The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
Open accessAbstract
We investigate whether private research investments are distorted away from long-term projects. Our theoretical model highlights two potential sources of this distortion: short-termism and the fixed patent term. Our empirical context is cancer research, where clinical trials—and hence, project durations—are shorter for late-stage cancer treatments relative to early-stage treatments or cancer prevention. Using newly constructed data, we document several sources of evidence that together show private research investments are distorted away from long-term projects. The value of life-years at stake appears large. We analyze three potential policy responses: surrogate (non-mortality) clinical-trial endpoints, targeted R&D subsidies, and patent design. (JEL D92, G31, I11, L65, O31, O34)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2019) · AEA Papers and Proceedings · doi:10.1257/pandp.109.612 · Cited by 10,902
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Appropriating the Returns from Industrial Research and Development
Levin, R. C., Klevorick, A. K., Nelson, R. R., Winter, S. G., Gilbert, R., & Griliches, Z. (1987) · Brookings Papers on Economic Activity · doi:10.2307/2534454 · Cited by 3,772
Schmookler, J. (1966) · Harvard University Press eBooks · doi:10.4159/harvard.9780674432833 · Cited by 3,101
Efficient Capital Markets, Inefficient Firms: A Model of Myopic Corporate Behavior
Stein, J. C. (1989) · The Quarterly Journal of Economics · doi:10.2307/2937861 · Cited by 2,563
Optimal Investment, Monitoring, and the Staging of Venture Capital
GOMPERS, P. A. (1995) · The Journal of Finance · doi:10.1111/j.1540-6261.1995.tb05185.x · Cited by 2,053
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Identifying Technology Spillovers and Product Market Rivalry
(2013) · Econometrica · doi:10.3982/ecta9466 · Cited by 1,758
Agency, Information and Corporate Investment
Stein, J. C. (2003) · Handbook of the Economics of Finance · doi:10.1016/s1574-0102(03)01006-9 · Cited by 1,347
Imitation Costs and Patents: An Empirical Study
Mansfield, E., Schwartz, M., & Wagner, S. (1981) · The Economic Journal · doi:10.2307/2232499 · Cited by 1,316
Standing on the Shoulders of Giants: Cumulative Research and the Patent Law
Scotchmer, S. (1991) · Journal of Economic Perspectives · doi:10.1257/jep.5.1.29 · Cited by 1,302
Patents and Innovation: An Empirical Study
Mansfield, E. (1986) · Management Science · doi:10.1287/mnsc.32.2.173 · Cited by 1,128 · cited 1×
“…play a key role in motivating innovation in the pharmaceutical industry, including industry interviews (Mansfield, Schwartz, and Wagner 1981; Mansfield 1986; Levin et al. 1987; Cohen, Nelson, and Walsh 2000), the cost structure of new drug development relative to the generic production…”
Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry
Acemoglu, D., & Linn, J. (2004) · The Quarterly Journal of Economics · doi:10.1162/0033553041502144 · Cited by 967
Why the Far-Distant Future Should Be Discounted at Its Lowest Possible Rate
Weitzman, M. L. (1998) · Journal of Environmental Economics and Management · doi:10.1006/jeem.1998.1052 · Cited by 961
The Emperor of All Maladies: A Biography of Cancer
Mukherjee, S. (2010) · Cited by 912
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Adams, C. P., & Brantner, V. V. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.420 · Cited by 907
Does Going Public Affect Innovation?
BERNSTEIN, S. (2015) · The Journal of Finance · doi:10.1111/jofi.12275 · Cited by 842
Optimal Patent Length and Breadth
Gilbert, R., & Shapiro, C. (1990) · The RAND Journal of Economics · doi:10.2307/2555497 · Cited by 839
Corporate Investment and Stock Market Listing: A Puzzle?
Asker, J., Farre-Mensa, J., & Ljungqvist, A. (2015) · Review of Financial Studies · doi:10.1093/rfs/hhu077 · Cited by 796
Estimates of the Value of Patent Rights in European Countries During the Post-1950 Period
Schankerman, M. A., & Pakes, A. (1986) · The Economic Journal · doi:10.2307/2233173 · Cited by 783
Patents and innovation: an empirical study
MansfieldE (1986) · Management Science · doi:10.5555/8407.8410 · Cited by 765
An Introduction to Medicinal Chemistry
Patrick, G. L. (2023) · Oxford University Press eBooks · doi:10.1093/hesc/9780198866664.001.0001 · Cited by 756
CAPITAL CHOICES: CHANGING THE WAY AMERICA INVESTS IN INDUSTRY
Porter, M. E. (1992) · Journal of Applied Corporate Finance · doi:10.1111/j.1745-6622.1992.tb00485.x · Cited by 735
Cronin, K. A., Ries, L. A. G., & Edwards, B. K. (2014) · Cancer · doi:10.1002/cncr.29049 · Cited by 699
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Jones, C. U., Hunt, D., McGowan, D. G., Amin, M. B., Chetner, M. P., Bruner, D. W., Leibenhaut, M. H., Husain, S. M., Rotman, M., Souhami, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012348 · Cited by 696
How Broad Should the Scope of Patent Protection Be?
Klemperer, P. (1990) · The RAND Journal of Economics · doi:10.2307/2555498 · Cited by 664
Invention, Growth and Welfare: A Theoretical Treatment of Technological Change.
Whitaker, J., & Nordhaus, W. D. (1970) · Economica · doi:10.2307/2551965 · Cited by 638
Identifying Technology Spillovers and Product Market Rivalry
Bloom, N., Schankerman, M., & Van Reenen, J. (2007) · National Bureau of Economic Research · doi:10.3386/w13060 · Cited by 621
Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Sullivan, J., Sarosdy, M. F., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251703 · Cited by 605
The Value of Health and Longevity
Murphy, K. M., & Topel, R. H. (2006) · Journal of Political Economy · doi:10.1086/508033 · Cited by 605
International Protection of Intellectual Property
Grossman, G. M., & Lai, E. L.-C. (2004) · American Economic Review · doi:10.1257/0002828043052312 · Cited by 546
Patent Buyouts: A Mechanism for Encouraging Innovation
Kremer, M. (1998) · The Quarterly Journal of Economics · doi:10.1162/003355398555865 · Cited by 490
End Points and United States Food and Drug Administration Approval of Oncology Drugs
Johnson, J. R., Williams, G., & Pazdur, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.072 · Cited by 479
Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer?
Welch, H. G. (2000) · JAMA · doi:10.1001/jama.283.22.2975 · Cited by 449
Do Stronger Patents Induce More Innovation? Evidence from the 1988 Japanese Patent Law Reforms
Sakakibara, M., & Branstetter, L. (2001) · The RAND Journal of Economics · doi:10.2307/2696399 · Cited by 419
Do Stronger Patents Induce More Innovation? Evidence from the 1988 Japanese Patent Law Reforms
Sakakibara, M., & Branstetter, L. (1999) · National Bureau of Economic Research · doi:10.3386/w7066 · Cited by 382
Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry
Finkelstein, A. (2004) · The Quarterly Journal of Economics · doi:10.1162/0033553041382166 · Cited by 321
Your money or your life: strong medicine for America's health care system
(2004) · Choice Reviews Online · doi:10.5860/choice.41-6562 · Cited by 315
Staged Financing: An Agency Perspective
Neher, D. V. (1999) · The Review of Economic Studies · doi:10.1111/1467-937x.00087 · Cited by 264
Evergreening, patent challenges, and effective market life in pharmaceuticals
Hemphill, C. S., & Sampat, B. N. (2012) · Journal of Health Economics · doi:10.1016/j.jhealeco.2012.01.004 · Cited by 262
Advances In The Prevention And Treatment Of Cardiovascular Disease
Weisfeldt, M. L., & Zieman, S. J. (2007) · Health Affairs · doi:10.1377/hlthaff.26.1.25 · Cited by 250
Surrogate Endpoints And FDA’s Accelerated Approval Process
Fleming, T. R. (2005) · Health Affairs · doi:10.1377/hlthaff.24.1.67 · Cited by 249
Developing Drugs For Developing Countries
Ridley, D. B., Grabowski, H. G., & Moe, J. L. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.313 · Cited by 198
Nordhaus' Theory of Optimal Patent Life: A Geometric Reinterpretation
Scherer, F. M. (1972) · American Economic Review · Cited by 194
Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease
Kozauer, N., & Katz, R. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1302513 · Cited by 193
Psaty, B. M. (1999) · JAMA · doi:10.1001/jama.282.8.786 · Cited by 187
Patent rights, product market reforms, and innovation
Aghion, P., Howitt, P. W., & Prantl, S. (2015) · Journal of Economic Growth · doi:10.1007/s10887-015-9114-3 · Cited by 182
Cancer Prevention: From 1727 to Milestones of the Past 100 Years
Lippman, S. M., & Hawk, E. T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1750 · Cited by 165
Valuing fatal risks to children and adults: Effects of disease, latency, and risk aversion
Hammitt, J. K., & Haninger, K. (2010) · Journal of Risk and Uncertainty · doi:10.1007/s11166-009-9086-9 · Cited by 159
Schumpeterian Profits in the American Economy: Theory and Measurement
Nordhaus, W. D. (2004) · National Bureau of Economic Research · doi:10.3386/w10433 · Cited by 151
Overview of the Hatch-Waxman Act and its impact on the drug development process.
Gj, M. (1999) · PubMed · Cited by 133
Allison, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2083 · Cited by 91
Off-label use of anticancer drugs
Levêque, D. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70280-8 · Cited by 88
Philipson, T., & Jena, A. B. (2005) · Forum for Health Economics & Policy · doi:10.2202/1558-9544.1005 · Cited by 84
An economic evaluation of the war on cancer
Lakdawalla, D., Sun, E. C., Jena, A. B., Reyes, C. M., Goldman, D. P., & Philipson, T. (2010) · Journal of Health Economics · doi:10.1016/j.jhealeco.2010.02.006 · Cited by 84
Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost
Lippman, S. M., & Brown, P. H. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1809 · Cited by 81
Market Power Screens Willingness-to-Pay*
Weyl, E. G., & Jean Tirole, Z. (2012) · The Quarterly Journal of Economics · doi:10.1093/qje/qjs032 · Cited by 81
Treatment options for actinic keratoses.
McINTYRE, W. J., Downs, M. R., & Bedwell, S. A. (2007) · PubMed · Cited by 77
The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development
Lathia, C., Amakye, D. D., Dai, W., Girman, C. J., Madani, S., Mayne, J. T., MacCarthy, P., Pertel, P. E., SEMAN, L. J., Stoch, A., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.69 · Cited by 71
The Return to Biomedical Research: Treatment and Behavioral Effects
Cutler, D., Kadiyala, S., Topel, R., et al. (2003) · Cited by 58
Response Rates, Survival, and Chemotherapy Trials
Pazdur, R. M. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1552 · Cited by 58
Modelling Survival Data in Medical Research, Second Edition
Collett, D. (1994) · Cited by 57
Patents and Research Investments: Assessing the Empirical Evidence
Budish, E. B., Roin, B. N., & Williams, H. (2016) · American Economic Review · doi:10.1257/aer.p20161091 · Cited by 56
Self-citationMeyskens, F. L., Curt, G. A., Brenner, D. E., Gordon, G., Herberman, R. B., Finn, O. J., Kelloff, G. J., Khleif, S. N., Sigman, C. C., & Szabo, E. M. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0014 · Cited by 51
Eisenberg, R. S. (2005) · PubMed · Cited by 49
Meropol, N. J., Kris, M. G., & Winer, E. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1125 · Cited by 38
Cost–effectiveness of statins revisited: lessons learned about the value of innovation
Lindgren, P., & Jönsson, B. (2011) · The European Journal of Health Economics · doi:10.1007/s10198-011-0315-1 · Cited by 23
Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets
Malani, A., & Philipson, T. (2011) · National Bureau of Economic Research · doi:10.3386/w17011 · Cited by 12
Introduction to Clinical Trials
Goffin, J. R. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse200 · Cited by 4
Cited by
The green economy transition: the challenges of technological change for sustainability
Söderholm, P. (2020) · Sustainable Earth · doi:10.1186/s42055-020-00029-y · Cited by 484
In the Shadow of a Giant: Medicare’s Influence on Private Physician Payments
Clemens, J., & Gottlieb, J. D. (2017) · Journal of Political Economy · doi:10.1086/689772 · Cited by 316
Race to the Bottom: Competition and Quality in Science
Hill, R., & Stein, C. (2025) · The Quarterly Journal of Economics · doi:10.1093/qje/qjaf010 · Cited by 40
Metadata
- Authors
- Budish, E., Roin, B. N., & Williams, H.
- Venue
- American Economic Review
- Publisher
- American Economic Association
- Published
- 2015-07-01
- Volume
- 105
- Issue
- 7
- Pages
- 2044-2085
- ISSN
- 0002-8282 (ISSN-L)
- OpenAlex
- W2107077262
- Cited by
- 302
- References
- 70
- FWCI
- 59.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.